20.01

15.50% -3.67

Newamsterdam Pharma Company Nv (NAMS)

Überblick Nachrichten Preisverlauf Financials Warum fällt NAMS? Forum Prognose

Schlusskurs vom Vortag:

$23.68

Offen:

$21.82

24-Stunden-Volumen:

3.01M

Relative Volume:

7.20

Marktkapitalisierung:

$1.85B

Einnahmen:

$14.09M

Nettoeinkommen (Verlust:

$-176.94M

KGV:

-7.5079

EPS:

-2.6652

Netto-Cashflow:

$-141.24M

1W Leistung:

-18.66%

1M Leistung:

+3.89%

6M Leistung:

+0.86%

1J Leistung:

+110.63%

1-Tages-Spanne:

$19.59

$22.44

1-Wochen-Bereich:

$19.59

$25.32

52-Wochen-Spanne:

$8.90

$26.35

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Firmenname

Newamsterdam Pharma Company Nv

Sektor

Healthcare (1193)

Branche

Biotechnology (683)

Telefon

35 206 2971

Adresse

GOOIMEER 2-35, NARRDEN

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NAMS's Discussions on Twitter

Vergleichen Sie NAMS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NAMS	20.01	1.85B	14.09M	-176.94M	-141.24M	-2.6652
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-18	Eingeleitet	Guggenheim	Buy
2024-01-16	Eingeleitet	Piper Sandler	Overweight
2023-10-30	Eingeleitet	RBC Capital Mkts	Outperform

Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten

Nov 20, 2024

Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online

Nov 20, 2024

NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha

Nov 20, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times

Nov 20, 2024

Nov 19, 2024

NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com

Nov 19, 2024

Trend Tracker for (NAMSW) - Stock Traders Daily

Nov 19, 2024

Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024

NewAmsterdam's Obicetrapib Achieves 41.5% LDL-C Reduction in Phase 3 Trial | NAMS Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com

Nov 15, 2024

GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 15, 2024

Nov 14, 2024

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St

Nov 14, 2024

Nov 13, 2024

When the Price of (NAMS) Talks, People Listen - Stock Traders Daily

Nov 13, 2024

Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024

Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024

Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 12, 2024

Nov 11, 2024

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Nov 11, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga

Nov 07, 2024

Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks

Nov 07, 2024

Nov 06, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat

Nov 06, 2024

NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 05, 2024

Nov 03, 2024

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024

Nov 01, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024

Oct 29, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times

Oct 29, 2024

Oct 25, 2024

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Oct 25, 2024

Oct 19, 2024

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Oct 19, 2024

Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

Oct 18, 2024

Oct 17, 2024

(NAMSW) Trading Report - Stock Traders Daily

Oct 17, 2024

Oct 14, 2024

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Oct 14, 2024

Oct 12, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

Oct 12, 2024

Oct 11, 2024